Targeted immunomodulation: a primer for intensivists

Malou Janssen^{1

2}, Henrik Endeman², Lieuwe D J Bos^{3

4}

Affiliations

¹ Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.
² Intensive Care, Erasmus MC, Rotterdam, The Netherlands.
³ Intensive Care, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. l.d.bos@amsterdamumc.nl.
⁴ Laboratory for Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. l.d.bos@amsterdamumc.nl.

Malou Janssen et al. Intensive Care Med. 2023 Apr.

. 2023 Apr;49(4):462-464.

doi: 10.1007/s00134-023-07009-8. Epub 2023 Mar 3.

Malou Janssen^{1

2}, Henrik Endeman², Lieuwe D J Bos^{3

4}

¹ Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.
² Intensive Care, Erasmus MC, Rotterdam, The Netherlands.
³ Intensive Care, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. l.d.bos@amsterdamumc.nl.
⁴ Laboratory for Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. l.d.bos@amsterdamumc.nl.

No abstract available

Conflict of interest statement

LB is supported by research funds from Innovative Health Initiative, ZonMW, Longfonds, Santhera and Amsterdam UMC.

1. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28:39–50. doi: 10.1038/s41591-021-01643-9. - DOI - PubMed
1. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14:121–137. doi: 10.1038/nrneph.2017.165. - DOI - PubMed
1. Isaacs JD, Burmester GR. Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis. 2020;79:991–993. doi: 10.1136/annrheumdis-2020-218019. - DOI - PMC - PubMed
1. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–874. doi: 10.1038/nri3552. - DOI - PMC - PubMed
1. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384:795–807. doi: 10.1056/NEJMOA2031994/SUPPL_FILE/NEJMOA2031994_DATA-SHARING.PDF. - DOI - PMC - PubMed